Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China · Delayed Price · Currency is CNY 33.78
-0.27 (-0.79%)
Feb 13, 2026, 3:00 PM CST
SHA:688076 Revenue
Jiangsu Sinopep-Allsino Biopharmaceutical had revenue of 478.90M CNY in the quarter ending September 30, 2025, with 13.82% growth. This brings the company's revenue in the last twelve months to 1.90B, up 20.52% year-over-year. In the year 2024, Jiangsu Sinopep-Allsino Biopharmaceutical had annual revenue of 1.62B with 57.21% growth.
Revenue (ttm)
1.90B
Revenue Growth
+20.52%
P/S Ratio
5.62
Revenue / Employee
936.75K
Employees
2,247
Market Cap
10.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.62B | 591.25M | 57.21% |
| Dec 31, 2023 | 1.03B | 382.26M | 58.69% |
| Dec 31, 2022 | 651.29M | 7.42M | 1.15% |
| Dec 31, 2021 | 643.87M | 77.00M | 13.58% |
| Dec 31, 2020 | 566.87M | 195.34M | 52.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.53B |
| Youcare Pharmaceutical Group | 2.55B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.96B |
| Aurisco Pharmaceutical | 1.62B |
| Vcanbio Cell & Gene Engineering Corp., | 1.47B |
| Liaoning Chengda Biotechnology | 1.47B |
| Chengdu Easton Biopharmaceuticals | 1.33B |
| Bio-Thera Solutions | 845.32M |